Historical Valuation
Alterity Therapeutics Ltd (ATHE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -19.03. The fair price of Alterity Therapeutics Ltd (ATHE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 3.52 USD , Alterity Therapeutics Ltd is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：3.52
Fair
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Alterity Therapeutics Ltd (ATHE) has a current Price-to-Book (P/B) ratio of 1016.71. Compared to its 3-year average P/B ratio of 909.80 , the current P/B ratio is approximately 11.75% higher. Relative to its 5-year average P/B ratio of 539.35, the current P/B ratio is about 88.51% higher. Alterity Therapeutics Ltd (ATHE) has a Forward Free Cash Flow (FCF) yield of approximately -11.70%. Compared to its 3-year average FCF yield of -59.50%, the current FCF yield is approximately -80.34% lower. Relative to its 5-year average FCF yield of -48.29% , the current FCF yield is about -75.77% lower.
P/B
Median3y
909.80
Median5y
539.35
FCF Yield
Median3y
-59.50
Median5y
-48.29
Competitors Valuation Multiple
AI Analysis for ATHE
The average P/S ratio for ATHE competitors is 1.76, providing a benchmark for relative valuation. Alterity Therapeutics Ltd Corp (ATHE.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ATHE
1Y
3Y
5Y
Market capitalization of ATHE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ATHE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ATHE currently overvalued or undervalued?
Alterity Therapeutics Ltd (ATHE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -19.03. The fair price of Alterity Therapeutics Ltd (ATHE) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 3.52 USD , Alterity Therapeutics Ltd is Undervalued By Fair .
What is Alterity Therapeutics Ltd (ATHE) fair value?
ATHE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Alterity Therapeutics Ltd (ATHE) is between +Inf to +Inf according to relative valuation methord.
How does ATHE's valuation metrics compare to the industry average?
The average P/S ratio for ATHE's competitors is 1.76, providing a benchmark for relative valuation. Alterity Therapeutics Ltd Corp (ATHE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Alterity Therapeutics Ltd (ATHE) as of Jan 10 2026?
As of Jan 10 2026, Alterity Therapeutics Ltd (ATHE) has a P/B ratio of 1016.71. This indicates that the market values ATHE at 1016.71 times its book value.
What is the current FCF Yield for Alterity Therapeutics Ltd (ATHE) as of Jan 10 2026?
As of Jan 10 2026, Alterity Therapeutics Ltd (ATHE) has a FCF Yield of -11.70%. This means that for every dollar of Alterity Therapeutics Ltd’s market capitalization, the company generates -11.70 cents in free cash flow.
What is the current Forward P/E ratio for Alterity Therapeutics Ltd (ATHE) as of Jan 10 2026?
As of Jan 10 2026, Alterity Therapeutics Ltd (ATHE) has a Forward P/E ratio of -3.81. This means the market is willing to pay $-3.81 for every dollar of Alterity Therapeutics Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Alterity Therapeutics Ltd (ATHE) as of Jan 10 2026?
As of Jan 10 2026, Alterity Therapeutics Ltd (ATHE) has a Forward P/S ratio of 0.00. This means the market is valuing ATHE at $0.00 for every dollar of expected revenue over the next 12 months.